CSN Login
Members Online: 11

Roche to share important oncology data at European Cancer Congress (ECC) including information on herceptin and TDM-1

dfd24
Posts: 82
Joined: Mar 2011

from http://www.biosciencetechnology.com/news/2013/09/roche-share-important-oncology-data-european-cancer-congress-ecc#.UkKMfijWFyM

Kadcyla:

  • Abstract #15: LATE BREAKING ABSTRACT T-DM1 for HER2-positive metastatic breast cancer (MBC): Primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice. ECC media briefing September 28. Proffered papers session, Saturday, September 28, 13:03 – 13:15 in Hall 7.1

Herceptin SC:

  • Abstract #1759: Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study. Poster session, Saturday, September 28, 09:30 – 16:30 in Hall 4

callerid
Posts: 99
Joined: Dec 2012

Very interesting. Do you know where these will be published.

Thanks

dfd24
Posts: 82
Joined: Mar 2011

i think if you look  up

European Cancer Congress (ECC) in the coming month they should talk about the results. also if you put in a google alert  for Kadcyla and Herceptin SC then any information would be emailed to your gmail mail account ( you can sign up for one if you don't have one ). also looking up the TH3RESA STUDY should bring results.best,

danièle

goty2001
Posts: 71
Joined: Jul 2012

Thanks for posting.  Hope it's good data.

 

Everybody should ensure they get tested for HER2+

Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2014 © Cancer Survivors Network